- $9.73bn
- $8.82bn
- $2.81bn
- 98
- 53
- 86
- 93
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,242 | 2,351 | 2,603 | 2,696 | 2,813 |
Cost of Revenue | |||||
Gross Profit | 1,886 | 1,943 | 2,117 | 2,156 | 2,220 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,724 | 1,959 | 2,209 | 2,292 | 2,341 |
Operating Profit | 518 | 392 | 394 | 404 | 473 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 541 | 396 | 387 | 385 | 486 |
Provision for Income Taxes | |||||
Net Income After Taxes | 428 | 307 | 331 | 322 | 395 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 428 | 307 | 331 | 322 | 395 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 428 | 307 | 331 | 322 | 395 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 7.26 | 5.42 | 6.03 | 5.47 | 7.43 |